Table 2 GO enrichment analysis for differentially regulated (≥ 1.5 fold-change) proteins

Biological process

 Cellular macromolecular complex subunit organization

5.34E−13

3.16E−05

 mRNA metabolic process

5.34E−13

2.20E−05

0.0099

4.85E−06

1.10E−25

 Cellular protein complex disassembly

3.46E−10

3.34E−05

 Protein complex disassembly

4.90E−10

Translational termination

6.69E−09

0.0044

 Cellular aromatic/cyclic compound metabolic process

0.0092

 Cellular nitrogen compound metabolic process

0.0139

1.92E−10

 Nucleic acid metabolic process

4.85E−06

 Cellular catabolic process

3.42E−05

5.02E−10

 Response to wounding

8.51E−14

 Actin filament-based process/cytoskeleton organisation

8.51E−14

 Acute inflammatory response

0.0197

2.58E−06

2.63E−09

1.57E−12

KEGG pathways

 Metabolic pathways

7.26E−11

4.41E−07

1.40E−05

2.75E−20

 Ribosome

4.72E−15

3.29E−16

 Focal adhesion

2.21E−05

3.74E−05

1.48E−18

6.72E−32

 Regulation of actin cytoskeleton

3.77E−06

4.82E−07

2.48E−11

 ECM-receptor interaction

0.0001

1.40E−05

2.92E−09

 Spliceosome

9.27E−06

9.31E−09

0.0005

 Proteasome

3.55E−05

4.29E−05

1.36E−10

 Oxidative phosphorylation

5.93E−05

4.13E−07

Disease association

 Carcinoma

9.60E−07

2.33E−07

8.97E−05

 Neoplasm invasiveness

7.87E−06

3.61E−08

5.76E−10

 Cancer or viral infections

6.40E−06

0.0007

 Anemia, hemolytic

2.15E−13

3.69E−12

1.50E−09

 Adhesion

5.10E−08

1.38E−06

1.39E−18

 Hematologic diseases

1.30E−10

 Protein deficiency

5.19E−08

2.13E−11

2.18E−10

 Cardiovascular diseases

5.04E−11

5.54E−10

 Huntington’s disease

1.10E−06

3.87E−15

2.11E−12